Schedule of Events

2018 ASCP Annual Meeting Schedule

 *of special interest to clinicians

Click on the following links to access the 2018 ASCP Annual Meeting program materials!

Complete Online Agenda with Presenters, Titles, and Abstracts

Presenter Disclosures

Poster Abstract Book

Oral Abstract Book

Program Book


 Monday, May 28, 2018
 8:00 AM  New Investigator Award (NIA) Workshop (Invitation Only)
 Tuesday, May 29, 2018
 8:30 AM  Conference Opening
 9:00 AM – 10:30 AM  Panel Sessions

  Identifying Moderators of Antidepressant Treatment and Strategies to Reduce Placebo Response: Findings from the EMBARC Study*
  It’s Not Just Autism: ASD and Associated Psychopathology and Cognitive Dysfunction*
  ACTIVE Update: Reduction in World Health Organization (WHO) Drinking Risks Level as a Primary Endpoint for Alcohol Treatment Trials
  Herbal and Nutraceutical Agents for Schizophrenia: Recent Clinical Trials*
 10:30 AM – 10:45 AM  Break
 10:45 AM – 12:15 PM  Panel Sessions

  Early-Phase Trials of Novel Interventions for Treatment-Resistant Depression
  Enhancing Medication Adherence in Clinical Trials: Challenges and Opprotunities
  The Opioid Epidemic: Crisis and Solutions*
  Pharmacodynamic and Cognitive Evaluation of CNS Drugs in Clinical Trials of Cannabis and Driving Impairment
 12:15 PM – 1:45 PM  Early Career Luncheon: Work Life Balance (RSVP Only)

  Michael Davis, MD, PhD, FDA
  Katharine Phillips, MD, Weill Cornell Medical College
  Dawn Ionescu, MD, Janssen Research and Development
  Mirjana Domakonda, MD, Hartford Hospital/Institute of Living
  Ross Baker, MD, Otsuka
  Kari Nations, PhD, Syneos Health
 2:00 PM – 4:00 PM  Pharmaceutical Pipelines
 4:00 PM – 4:15 PM  Break
 4:15 PM – 5:30 PM  Individual Research Reports
 6:15 PM – 7:45 PM  New Investigator Awards Ceremony
 Wednesday, May 30, 2018
 6:30 AM  Annual ASCP Fun Run/Walk – Open to all attendees
 8:30 AM – 10:00 AM  Regulatory Plenary: Autism Spectrum Disorder

  John Newcomer, MD, Chair
  Tiffany Farchione, MD: FDA
 Valentina Mantua, MD: AIFA
 10:00 AM – 10:15 AM  Break
 10:15 AM – 11:15 AM  ASCP Lifetime Awardee Talk
 11:15 AM – 1:00 PM  Poster Session I with Lunch
 1:00 PM – 2:30 PM  Panel Sessions

   Treatment of Resistant Depression with Ketamine: Similarities and Differences With ECT*
   Geriatric Psychopharmacology Update: Findings, Challenges, and New Opportunities*
   New Perspectives on Treatment Resistant Schizophrenia (TRS)
   Long-Term Medication for Axis I Disorders: Lifetime Treatment or Not?*
 2:30 PM – 2:45 PM  Break
 2:45 PM – 4:45 PM  Workshop Sessions

  Early Career Workshop: How to Get Published
  Joint ASCP/AFSP Workshop: Inclusion of Suicidal Individuals in Treatment Trials: Now is the Time
  FDA’s Initiatives to Optimize Pediatric Clinical Development for Psychiatric Products
  30 Years of the PANSS in Schizophrenia: Where Are We Now and Where Are We headed?
 5:00 PM – 6:00 PM  ASCP Business Meeting and Reception (Members Only)
 6:00 PM – 7:00 PM  ASCP Reception
 Thursday, May 31, 2018
 8:15 AM – 9:45 AM  Keynote Plenary

  Marlene Freeman, MD, Chair
  Sandra Comer, PhD: Opioid Use Across the Lifespan
  Helen Mayberg, MD: Strategies to Refine and Optimize DBS for Depression: A Multidisciplinary Translational Approach
  J John Mann, MD: Suicidal Behavior Across the Life Cycle
 9:45 AM – 10:00 AM  Break
 10:00 AM – 12:30 PM  Federal Agency Directors Plenary

  Michael Thase, MD, Chair
  Lorenzo Leggio, MD, PhD.: NIAAA Update
  Ivan Montoya, MD, MPH: Research Priorities of NIDA’s Medications Development Program
  Shelli Avenevoli, PhD: NIMH Updates and Research Priorities
  Richard Nakamura, PhD: CSR Update
Lori Davis, MD: VA Update
  Ronald Hoover, PhD: DoD Update
 12:30 PM – 2:00 PM  Poster Session II with Lunch
 2:00 PM – 3:30 PM Clinical Updates in Psychopharmacology Session*

  Holly Swartz, MD, Chair
  Anita Clayton, MD: Pathophysiology, Assessment, and Treatment of Sexual Dysfunction
  Rajnish Mago, MD: Which Pharmacogenomic Tests are Useful for Predicting and Reducing Adverse Effects?
  Anthony Rostain, MD: Update on Treating ADHD
 3:30 PM – 3:45 PM  Break
 3:45 PM – 5:45 PM  Workshop Sessions

  Challenges and Implementation of CNS Clinical Trials
  Leadership Skills for Mid-Career Professional
  Behavioral and Psychological Symptoms of Dementia: Perspectives in Clinical Development from the Division of Psychiatry Products, Food and Drug Administration*
  Women’s Mental Health across the Lifespan: Knowledge Gained
and Evidence Gaps*
 Friday, June 01, 2018
 8:30 AM – 10:00 AM  Panel Sessions

  Neuroplasticity and Ketamine Response in Depression
  Controversies in Bipolar Depression Across the Lifespan*
  Optimizing Signal Detection in Psychiatric Clinical Trials
  Challenges in Translating Suicidality Concepts for International Trials across the Lifespan
 10:00 AM – 10:15 AM  Break
 10:15 AM – 11:45 AM  Regulatory Wrap-Up Plenary

  John Newcomer, MD, Chair
  Tiffany Farchione, MD: FDA
  Mitchell Mathis, MD: FDA

Valentina Mantua, MD: AIFA

 12:00 PM  Meeting Adjourns

 *of special interest to clinicians